Roche has staked a claim to use its oral selective oestrogen receptor degrader (SERD) giredestrant as a second-line therapy for breast cancer, regardless of a patient's ESR1 mutation status. Top-line ...

Aashika’s near two decades stint in business and finance journalism has led her to report, write, edit and lead teams covering public investing, private investing and personal investing both in India ...

Taylor Swift more or less plays on repeat when I’m driving around with our kids, so the recent arrival of The Eras Tour film, a new version of “Cruel Summer,” and 1989 (Taylor’s Version) all generated ...